Ionis Pharms Inc Company Profile
What is the competitive landscape for IONIS PHARMS INC
IONIS PHARMS INC has three approved drugs.
There are ten US patents protecting IONIS PHARMS INC drugs.
Drugs and US Patents for Ionis Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharms Inc | TRYNGOLZA (AUTOINJECTOR) | olezarsen sodium | SOLUTION;SUBCUTANEOUS | 218614-002 | Jun 24, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Ionis Pharms Inc | TRYNGOLZA (AUTOINJECTOR) | olezarsen sodium | SOLUTION;SUBCUTANEOUS | 218614-002 | Jun 24, 2026 | RX | Yes | Yes | 9,157,082 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | 9,315,811 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ionis Pharms Inc | TRYNGOLZA (AUTOINJECTOR) | olezarsen sodium | SOLUTION;SUBCUTANEOUS | 218614-001 | Dec 19, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Ionis Pharms Inc | TRYNGOLZA (AUTOINJECTOR) | olezarsen sodium | SOLUTION;SUBCUTANEOUS | 218614-001 | Dec 19, 2024 | RX | Yes | Yes | 9,127,276 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Ionis Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 7177127 | ⤷ Start Trial |
| Japan | 2024116224 | ⤷ Start Trial |
| Spain | 2961686 | ⤷ Start Trial |
| South Korea | 20230006933 | ⤷ Start Trial |
| South Korea | 101857707 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ionis Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3137091 | C20265016 | Finland | ⤷ Start Trial | |
| 3524680 | 28/2025 | Austria | ⤷ Start Trial | PRODUCT NAME: EPLONTERSEN, OPTIONAL IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 (MITTEILUNG) 20250307 |
| 3137091 | 2026C/732 | Belgium | ⤷ Start Trial | PRODUCT NAME: DONIDALORSEN; AUTHORISATION NUMBER AND DATE: EU/1/25/2001 20260120 |
| 3524680 | 301341 | Netherlands | ⤷ Start Trial | PRODUCT NAME: EPLONTERSEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/24/1875 20250307 |
| 2991656 | 122026000005 | Germany | ⤷ Start Trial | PRODUCT NAME: OLEZARSEN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; AUTHORISATION NO/DATE: EU/1/25/1969 20250917 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

